Sarepta Therapeutics (SRPT) Shares on Watch Amid Chatter of Secondary Stock Offering

Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer

Oppenheimer analyst Michelle Gilson notes US Patent and Trademark Office ruled in favor of Sarepta (NASDAQ: SRPT) for Patents 7,960,541 and 7,807,816 in its patent interference proceeding (interference number 106,008).

Gilson notes these cover composition of matter for eteplirsen, giving the Sarepta freedom to operate... More

Sarepta Therapeutic (SRPT) PT Raised to $66 at Wedbush

Wedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $66.00 (from $36.00) after the FDA approved eteplirsen.

Behanna commented, "In line with our expectations after FDA asked for new data, eteplirsen has received accelerated... More

Sarepta Therapeutics (SRPT) volatility pulls back on sharp rally on FDA approval

Sarepta Therapeutics (NASDAQ: SRPT) is recently up $2.05 to $50.99 in the premarket after saying it sees the U.S. annual cost of eteplirsen at $300,000, a day after rallying 73% on the FDA approval of eteplirsen. September weekly call option implied volatility is at 145, October is... More

UPDATE: Cowen Upgrades Sarepta Therapeutic (SRPT) to Outperform

(Updated - September 20, 2016 8:48 AM EDT)

Cowen upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Market Perform to Outperform with a price target of $64 after the FDA approved Exondys 51.

Analyst Ritu Baral said, "Following today's approval of Exondys 51, SRPT announced average weight-based net,... More